AstraZeneca Divests Antidiabetics To 3SBio In New China Growth Plan
Executive Summary
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
You may also be interested in...
New Products, Expanding Coverage To Propel AstraZeneca In China
For the first time, new product launches start driving growth for AstraZeneca in China where a new national reimbursement scheme is likely to further expand market access to five products but that comes with a steep price cut.
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Diabetes Tsunami? China Eyes More Modern Therapies Under 2025 Plan
Diabetes poses a triple whammy and is likely to cripple China's health care system in near future. To counter, the Chinese government looks at total disease management, long-acting insulins and GLP-1 products.